WASHINGTON, Feb 16 - Now that the hoopla surrounding the human genome has died down, the Human Genome Project's future plans include finishing the most difficult parts of the genome, supporting the development for new sequencing technologies, selecting new organisms to sequence, and awarding a contract for an independent quality assessment center to help meet its goal of verified 99.99 percent accuracy.  

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.